Compile Data Set for Download or QSAR
maximum 50k data
Found 41 Enz. Inhib. hit(s) with all data for entry = 9327
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298285(US10123984, Example 2A | US10744104, Example 2A | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458421(US10744104, Example 14A | US11547687, Example 14A ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458416(US10744104, Example 11-2 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298308(US10123984, Example 8-3 | US10744104, Example 8-3 ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298307(US10123984, Example 8-2 | US10744104, Example 8-2 ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458409(US10744104, Example 7B | US11547687, Example 8-3 |...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298305(US10123984, Example 6A | US10744104, Example 6A | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458407(US10744104, Example 5-17)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458406((2R,4R)-5-(3-Chlorobiphenyl-4-yl)-2-hydroxy-4-(oxa...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458405(US10744104, Example 5-14 | US20230285340, Example ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458404(US10744104, Example 5-13)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458403(US10744104, Example 5-9)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458402(US10744104, Example 5-5 | US20230285340, Example 5...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458388(US10744104, Example 1 | US10744104, Example 5-1 | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458399(US10744104, Example 3D | US20230285340, Example 3D)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298295(BDBM582703 | US10123984, Example 3A | US10123984, ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298294(US10123984, Example 2V | US10744104, Example 2V | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298293(US10123984, Example 2U | US10744104, Example 2U | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298292(US10123984, Example 2T | US10744104, Example 2T | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298286(US10123984, Example 2F | US10744104, Example 2F | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298288(US10123984, Example 2H | US10744104, Example 2H | ...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458395((R)-5-Biphenyl-4-yl-2-hydroxy-4-(oxalylamino)penta...)
Affinity DataKi: <1nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458423(US10744104, Example 14F | US11547687, Example 14F ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298316(US10123984, Example 11-1 | US10744104, Example 11-...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298326(US10123984, Example 16 | US10744104, Example 16 | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298287(US10123984, Example 2G | US10744104, Example 2G | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298319(US10123984, Example 11-4 | US10744104, Example 11-...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298289(US10123984, Example 2I | US10744104, Example 2I | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298321((R)-3-[N-(3′-Chlorobiphenyl-4-ylmethyl)-N...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298315((2S,4R)-5-(3'-Fluorobiphenyl-4-yl)-2-hydroxymethyl...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298312(US10123984, Example 9A | US10744104, Example 9A | ...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298297((2R,4R)-5-(3-Chlorobiphenyl-4-yl)-2-hydroxy-4-(oxa...)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458413(US10744104, Example 8-5 | US11547687, Example 8-6)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458412(US10744104, Example 8-4 | US11547687, Example 8-4)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458422(US10744104, Example 14C)
Affinity DataKi:  3.55nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298318(US10123984, Example 11-3 | US10744104, Example 11-...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298325((2R,4S)-5-Biphenyl-4-yl-2-hydroxy-5-methyl-4-(oxal...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458426(US10744104, Example 8-6)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298290(US10123984, Example 2J | US10744104, Example 2J | ...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM298320(3-(N-Biphenyl-4-ylmethyl-N′-oxalylhydrazino)...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetNeprilysin(Homo sapiens (Human))
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM458388(US10744104, Example 1 | US10744104, Example 5-1 | ...)
Affinity DataKi:  35.5nMAssay Description:The assays were performed in 384-well white opaque plates at 37° C. using the fluorogenic peptide substrates at a concentration of 10 μM in Assa...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent